1. MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms
   Florian Posch et al, 2021, Cancers CrossRef
2. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
   Christian Mayr et al, 2021, Cancers CrossRef